多帕菲联合卡铂新辅助化疗治疗巨块型宫颈癌35例分析  

Analysis of neoadjuvant chemotherapy with Docetaxel plus Carboplatin in treatment for 35 cases with bulky cervical carcinoma

作　　者：吴英[1] 曹兰琴[1] 

机构地区：[1]中南大学湘雅医院妇科,湖南长沙410008

出　　处：《中国现代医学杂志》2008年第11期1613-1614,共2页China Journal of Modern Medicine

摘　　要：目的探讨术前多帕菲联合卡铂化疗对巨块型宫颈癌的疗效及安全性。方法选择病理确诊的35例Ⅰb～Ⅱb期巨块型宫颈癌患者,术前行多帕菲+卡铂化疗2个疗程,化疗后行宫颈癌根治术。结果新辅助化疗临床有效率达91.42%,手术切除率100%。结论术前多帕菲联合卡铂化疗可使Ⅰb～Ⅱb期巨型宫颈癌临床分期降低,提高手术成功率。[Objective] To observe the efficacy and safety on treating bulky cervical cancer with Dopafei and Carboplatin before operation. [Methods] 35 eases of Ⅰ b- Ⅱb period bulky cervical cancer were treated by untied chemotherapy of Dopafei and Carboplatin during two cycles before operation, after chemotherapy they were treated by radical hysterectomy. [Results] After the neoadjuvant chemotherapy （NACT）, the therapeutic effective rate can obtain 91.42%, and all of sufferers can be treated by operation. [Conclusions] Clinical staging of Ⅰ b-Ⅱ b period bulky cervical cancer can be depressed by untied chemotherapy of Dopafel and Carboplatin before operation, at the same time, the the successful rate of operation can be raised.

关 键 词：宫颈癌 新辅助化疗 手术治疗 

分 类 号：R984[医药卫生—药品]